TITLE: Preparation of triazolopyrimidinamines as adenosine A2a receptor antagonists

INVENTOR(S): Matasi, Julius J.; Caldwell, John P.; Tulshian, Deen; Silverman, Lisa S.; Neustadt, Bernard R.

PATENT ASSIGNEE(S): Schering Corporation, USA

SOURCE: PCT Int. Appl., 97 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003048164	A2	20030612	WO 2002-US38134	20021126 <--
WO 2003048164	A3	20031016		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SC, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2468681	A1	20030612	CA 2002-2468681	20021126 <--
AU 2002346572	A1	20030617	AU 2002-346572	20021126 <--
US 2003212080	A1	20031113	US 2002-304504	20021126 <--
US 7041666	B2	20060509		
EP 1453835	A2	20040908	EP 2002-784641	20021126 <--
EP 1453835	B1	20060215		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
HU 2004002270	A2	20050228	HU 2004-2270	20021126 <--
CN 1596258	A	20050316	CN 2002-823922	20021126 <--
JP 2005511698	T	20050428	JP 2003-549354	20021126 <--
AT 317844	T	20060315	AT 2002-784641	20021126 <--
ES 2258164	T3	20060816	ES 2002-784641	20021126 <--
ZA 2004004160	A	20050408	ZA 2004-4160	20040527 <--
MX 2004PA05156	A	20040811	MX 2004-PA5156	20040528 <--
HK 1064100	A1	20060714	HK 2004-106913	20040911 <--

PRIORITY APPLN. INFO.: US 2001-334293P P 20011130 <--
WO 2002-US38134 W 20021126 <--

OTHER SOURCE(S): MARPAT 139:36539

GI



I

AB Title compds. [I; R = (substituted) heteroaryl, Ph, cycloalkenyl, C(:CH2)Me, C.tplbond.CMe, dihydrofuryl, tetrahydrofuryl, CH:CMe2, C.tplbond.CCH2OH, CH:CHMe; R2 = WX, NR19(CH2)mWX, NR19CHMeWX, (substituted) alkyl, alkenyl,

amino; R3 = H, halo, alkyl, CF3, alkoxy, alkoxyalkyl, hydroxyalkyl, alkylamino, aryl, heteroaryl, cyano, etc.; R19 = H, alkyl, alkylcycloalkyl, cycloalkylalkyl, alkoxyalkyl; m = 1-3; W = (substituted) aryl, heteroaryl; X = H, (substituted) amino, etc.], were prepared as antiparkinsonians (no data). Thus, 2-amino-4-chloro-6- methylpyrimidine was heated with 2-furoic hydrazide in BuOH at 90° for 16 h to give a solid product which was heated with N,O-bis(trimethylsilyl)acetamide at 120° overnight to give I (R = 2-furyl; R2 = Me; R3 = H). Pharmaceutical compns. comprising I are claimed.

IT 394652-85-8P 540752-76-9P 540752-84-9P
540752-89-4P 540752-95-2P 540752-98-5P
540753-07-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of triazolopyrimidinamines as adenosine A2a receptor antagonists)

RN 394652-85-8 ZCAPLUS
CN 2-Furancarboxylic acid, 2-(2-amino-6-chloro-4-pyrimidinyl)hydrazide (CA INDEX NAME)



RN 540752-76-9 ZCAPLUS
CN 2-Furancarboxylic acid, 2-[2-amino-6-[3-(1-methylethyl)phenyl]-4-pyrimidinyl]hydrazide (CA INDEX NAME)



RN 540752-84-9 ZCAPLUS
CN 2-Furancarboxylic acid, 2-[2-amino-6-[5-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-3-pyridinyl]-4-pyrimidinyl]hydrazide (CA INDEX NAME)



RN 540752-89-4 ZCAPLUS
CN 1-Piperazinecarboxylic acid, 4-[3-[2-amino-6-[2-(2-furanylcarbonyl)hydrazino]-4-pyrimidinyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 540752-95-2 ZCAPLUS
CN 2-Furancarboxylic acid, 2-[2-amino-6-[3-(1-hydroxyethyl)phenyl]-4-pyrimidinyl]hydrazide (CA INDEX NAME)



RN 540752-98-5 ZCAPLUS
CN 2-Furancarboxylic acid, 2-(2-amino-1,6-dihydro-6-oxo-4-pyrimidinyl)hydrazide (CA INDEX NAME)



RN 540753-07-9 ZCAPLUS
CN 1-Piperidinecarboxylic acid, 4-[3-[2-amino-6-[2-(2-furanylcarbonyl)hydrazino]-4-pyrimidinyl]phenyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)